Abstract:The gut microbiome emerges as an integral component of precision medicine because of its signature variability among individuals and its plasticity, which enables personalized therapeutic interventions, especially when integrated with other multiomics data. This promise is further fueled by advances in next-generation sequencing and metabolomics, which allow in-depth high-precision profiling of microbiome communities, their genetic contents, and secreted chemistry. This knowledge has advanced our understanding of our microbial partners, their interaction with cellular targets, and their implication in human conditions such as inflammatory bowel disease (IBD). This explosion of microbiome data inspired the development of next-generation therapeutics for treating IBD that depend on manipulating the gut microbiome by diet modulation or using live products as therapeutics. The current landscape of artificial microbiome therapeutics is not limited to probiotics and fecal transplants but has expanded to include community consortia, engineered probiotics, and defined metabolites, bypassing several limitations that hindered rapid progress in this field such as safety and regulatory issues. More integrated research will reveal new therapeutic targets such as enzymes or receptors mediating interactions between microbiota-secreted molecules that drive or modulate diseases. With the shift toward precision medicine and the enhanced integration of host genetics and polymorphism in treatment regimes, the following key questions emerge: How can we effectively implement microbiomics to further personalize the treatment of diseases like IBD, leveraging proven and validated microbiome links? Can we modulate the microbiome to manage IBD by altering the host immune response? In this review, we discuss recent advances in understanding the mechanism underpinning the role of gut microbes in driving or preventing IBD. We highlight developed targeted approaches to reverse dysbiosis through precision editing of the microbiome. We analyze limitations and opportunities while defining the specific clinical niche for this innovative therapeutic modality for the treatment, prevention, and diagnosis of IBD and its potential implication in precision medicine.

Exploring the complex role of gut microbiome in the development of precision medicine strategies for targeting microbial imbalance-induced colon cancer

Exploring the Role of Gut Microbiome in Colon Cancer

Host-Gut Microbiota Metabolic Interactions and Their Role in Precision Diagnosis and Treatment of Gastrointestinal Cancers

Role of the gut microbiota in anticancer therapy: from molecular mechanisms to clinical applications

The Colloquy between Microbiota and the Immune System in Colon Cancer: Repercussions on the Cancer Therapy

Host-Microbiome Interaction and Cancer: Potential Application in Precision Medicine

Exploring the Gut Microbiome’s Role in Colorectal Cancer: Diagnostic and Prognostic Implications

Gut microbiota and colorectal cancer: insights into pathogenesis for novel therapeutic strategies

Gut Microbiome–Colorectal Cancer Relationship

Role of the Microbiome in the Diagnosis and Management of Gastroesophageal Cancers

Shaping the future of gastrointestinal cancers through metabolic interactions with host gut microbiota

Role of Gut Microbiome in Cancer Treatment

The Gut Microbiome Advances Precision Medicine and Diagnostics for Inflammatory Bowel Diseases

Gut microbiota, an emergent target to shape the efficiency of cancer therapy

Role of Gut Microbiota in the Development and Treatment of Colorectal Cancer

Critical role of the gut microbiota in immune responses and cancer immunotherapy

Targeting the microbiome to improve human health with the approach of personalized medicine: Latest aspects and current updates

Gut microbiota modulation: a novel strategy for prevention and treatment of colorectal cancer

Exploring the gut microbiome and head and neck cancer interplay

Exploring the Role of the Gut Microbiota in Modulating Colorectal Cancer Immunity

Targeting the gut microbiota for cancer therapy